CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2024; 8: (7) ; 112-114 ; DOI: 10.12208/j.ijcr.20240271.

The application of ilozumab in the treatment of coronary heart disease
依洛尤单抗在冠心病降脂治疗中的应用

作者: 赵梅, 周兴鹏, 崔耀金 *

山东省青岛西海岸新区人民医院 山东青岛

*通讯作者: 崔耀金,单位:山东省青岛西海岸新区人民医院 山东青岛;

发布时间: 2024-07-27 总浏览量: 252

摘要

目的 讨论在冠心病降脂治疗中应用依洛尤单抗的临床效果。方法 选取本院收治的冠心病患者70例(研究时间2021年7月-2022年7月),根据分层随机抽样方法分组,对照组(n=35)采用他汀类药物治疗,治疗组(n=35)在使用他汀类药物基础上再应用依洛尤单抗进行治疗。比较两组患者用药后的血脂水平、心功能指标以及治疗期间出现的不良反应情况。结果 治疗组用药干预后的TC、TG、LDL-C水平比对照组低,且CO、SVC、LVEF水平高于对照组(P<0.05);治疗组用药治疗期间出现的不良反应发生率小于对照组(P<0.05)。结论 依洛尤单抗药物在冠心病降脂治疗过程中具有积极药物效果,可以有效降低患者血脂水平,改善心功能状态,且安全性高,值得临床应用。

关键词: 冠心病;降脂治疗;依洛尤单抗;血脂水平

Abstract

Objective To discuss the clinical efficacy of using ilozumab in lipid-lowering treatment for coronary heart disease.
Methods 70 patients with coronary heart disease admitted to our hospital (study period: July 2021 to July 2022) were selected and divided into two groups using a stratified random sampling method. The control group (n=35) received statin therapy, while the treatment group (n=35) received ilozumab in addition to statin therapy. Compare the blood lipid levels, cardiac function indicators, and adverse reactions during treatment between two groups of patients after medication.
Results TC TG and LDL-C levels were lower than the control group, and CO The levels of SVC and LVEF were higher than those of the control group (P<0.05); The incidence of adverse reactions during medication treatment in the treatment group was lower than that in the control group (P<0.05).
Conclusion   Yiluoyumab has a positive drug effect in the lipid-lowering treatment of coronary heart disease, which can effectively reduce blood lipid levels in patients, improve cardiac function, and has high safety. It is worthy of clinical application.

Key words: Coronary heart disease; Lipid-lowering therapy; Ilozumab; Blood lipid level

参考文献 References

[1] 郑贝贝. 依洛尤单抗在冠心病降脂治疗中的疗效与安全性[J]. 临床研究, 2023, 31 (03): 103-106.

[2] 申晨, 王晓丽, 卢英霞等. 依洛尤单抗对青年初发急性心肌梗死患者降脂作用的疗效分析[J]. 中国循证心血管医学杂志, 2023, 15 (07): 805-807+817.

[3] 李伟, 刘洋, 李一等. 动脉粥样硬化性心血管疾病-冠脉多支病变患者应用依洛尤单抗的疗效与安全性研究[J]. 河北医药, 2022, 44 (23): 3573-3577.

[4] 胡耀红, 王慧峰, 邬冬梅等. 依洛尤单抗对冠心病合并高脂血症病人血脂和超敏C反应蛋白的影响[J]. 中西医结合心脑血管病杂志, 2022, 20 (20): 3774-3776.

[5] 孙刘波. 依洛尤单抗联合依折麦布治疗难治性血脂升高并冠心病的有效性与可行性分析[J]. 中国疗养医学, 2022, 31 (02): 217-219.

[6] 孙静, 安健. 依洛尤单抗在冠心病降脂治疗中的疗效与安全性探讨[J]. 中国药物与临床, 2022, 22 (06): 544-548.

[7] 文仙仙.探讨依洛尤单抗在冠心病患者降脂治疗中的效果[J].中西医结合心血管病电子杂志,2022,10(21):40-42+36.

[8] 叶斐,王腾,杨昕宇,等.依洛尤单抗对冠心病合并高脂血症患者血脂水平、生活质量及预后的影响[J].现代医学与健康研究电子杂志,2024,8(06):73-75.

引用本文

赵梅, 周兴鹏, 崔耀金, 依洛尤单抗在冠心病降脂治疗中的应用[J]. 国际临床研究杂志, 2024; 8: (7) : 112-114.